Mechanisms of Tumor Promotion by Surrounding Cells

A new study published in Nature shows that the physical forces around a tumor can drive cancer cells to dramatically change their behavior. Instead of simply dividing quickly, cells under mechanical pressure can activate a program that makes them more invasive and resistant to treatment, adding new complexity to how cancers spread and survive. Researchers used a zebrafish model of melanoma to observe how tumor cells react when tightly confined by surrounding tissues. They discovered that the stress of confinement triggered a switch from rapid growth to what the team called “neuronal invasion,” enabling cells to migrate and infiltrate nearby tissue. At the heart of this transformation is HMGB2, a DNA-bending protein that changes how genetic material is packaged, exposing genes linked to invasiveness. The study also revealed that cancer cells protect themselves under stress by reshaping their internal skeleton, forming a cage-like structure around the nucleus. This involves the LINC complex, which connects the cell skeleton to the nuclear envelope and guards against DNA damage caused by pressure. The findings highlight how the tumor microenvironment plays an active role in shaping cancer progression. By identifying the proteins and structures involved in this switch, researchers hope to develop therapies that block or even reverse the transition to an invasive, drug-resistant state. Research Paper 📄 PMID: 40866703

🔬 Unlocking the Potential of the Tumor Microenvironment (TME) 🔎 💡 Cancer remains a formidable global health challenge, with metastasis responsible for most cancer-related deaths. A recent review in the Journal of Hematology & Oncology highlights the intricate role of the TME in shaping cancer progression, therapeutic resistance, and treatment innovation. Here are the key takeaways from this groundbreaking research 👇: 🔬 Decoding the Tumor Microenvironment (TME): A Complex Ecosystem The TME isn’t just a backdrop—it actively orchestrates cancer progression. It comprises: 🔹 Cancer-Associated Fibroblasts (CAFs): The most abundant stromal cells in tumors. These cells remodel the extracellular matrix (ECM), secrete cytokines like TGF-β, and drive processes like Epithelial-Mesenchymal Transition (EMT), which enhances cancer invasiveness and therapy resistance. 🔹 Immune Cells: ▪️ TAMs (Tumor-Associated Macrophages): Modulate immune suppression and support metastasis. ▪️ TANs (Tumor-Associated Neutrophils): Trigger EMT and secrete IL-17A, activating JAK2/STAT3 signaling to boost migration and invasion. ▪️ Natural Killer (NK) Cells: These innate immune cells directly attack tumors but can be influenced by the TME to suppress their activity. 🔹 Extracellular Matrix (ECM): Provides structural support but also facilitates EMT through matrix stiffness and signaling pathways like YAP/TAZ activation. 💡 Innovative Therapeutic Strategies 🧬 Targeting EMT: 🔹 Key signaling molecules like TGF-β, Wnt/β-catenin, and HIF-1α are major drivers of EMT. Strategies that inhibit these pathways could disrupt metastasis. 🔹 Hypoxia-Driven EMT: Tumor hypoxia stabilizes HIF-1α, upregulates Snail and Twist, and promotes invasion. 🛠️ Disrupting the TME’s Support System: ❌ Blocking CAF activity: Targeting secreted factors like IL-6, TGF-β, and periostin has shown promise in pre-clinical models. ✔️ Modulating immune responses: Inhibitors targeting immune checkpoints and cytokine signaling (e.g., IL-6/TGF-β crosstalk) can re-activate anti-tumor immunity. ✨ Emerging Insights: 1️⃣ 3D Models of TME: New biomimetic culture systems mimic ECM properties, offering better platforms for testing drugs. 2️⃣ Dual Roles of TME Components: Molecules like TGF-β act as tumor suppressors in early cancer stages but drive metastasis later, underscoring the need for context-specific interventions. 3️⃣ Therapeutic Resistance: EMT confers stem-like properties to cancer cells, enhancing drug resistance and promoting relapse. 📊 Key Findings 🔹 Matrix Stiffness: Increased ECM rigidity drives EMT by activating YAP/TAZ and downstream pathways like TWIST1 and Snail. 🔹 CAFs and Growth Factors: CAF-derived HGF, EGF, and FGF-2 promote EMT and metastasis. 🔹 Immune Suppression: MDSCs and Tregs within the TME inhibit T-cell activity, allowing cancer cells to evade immune surveillance. #CancerResearch #TumorMicroenvironment #OncologyInnovation #EMT #Immunotherapy

A striking new Nature Magazine paper sharpens an increasingly important concept in cancer biology: oncogenic epithelial cells do not merely adapt to a permissive microenvironment — they actively instruct its formation. Using integrated single-cell, spatial, and functional approaches, the study shows that KRASG12D-mutant alveolar type II cells rapidly enter regenerative-like states that function as signaling hubs, coordinating stromal and immune reprogramming at the very earliest stages of lung tumorigenesis. Through amphiregulin secretion, these mutant epithelial cells activate EGFR signaling in neighboring fibroblasts, inducing an injury-like fibrotic program. Those fibroblasts then expand and reprogram alveolar macrophages, amplifying inflammatory signaling and reinforcing epithelial plasticity. The result is a self-sustaining epithelial-stromal-immune circuit that establishes a tumor-permissive niche before overt malignant outgrowth. What is especially compelling is that disruption of the amphiregulin-EGFR axis prevented early niche formation and abrogated tumor initiation, highlighting a potentially actionable vulnerability at a stage of disease we still understand far too incompletely. More broadly, this work reinforces a principle that is gaining increasing traction across cancer types: oncogenic events within incipient tumor cells can direct surrounding normal tissues to build the very ecosystem required for tumor emergence. It echoes, in a different biological context, our earlier work showing that oncogenic HRAS can instruct the surrounding melanoma microenvironment to support tumorigenesis, in that case through induction of angiogenesis (Chin et al Nature 1999). An elegant and important study. Check it out. https://lnkd.in/g3wX289i

New Insights into Tumor–Stroma Crosstalk MIRO2-mediated mitochondrial transfer from cancer cells induces cancer-associated fibroblast differentiation A fascinating new study from Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland shows that cancer cells can transfer their mitochondria to nearby fibroblasts, reprogramming them into cancer-associated fibroblasts (CAFs) that fuel tumor growth. 🔑 Key Highlights: • Cancer-to-fibroblast mitochondrial transfer reshapes fibroblast metabolism, activates CAF markers, and drives a protumorigenic secretome/matrisome. • This process requires MIRO2, a mitochondrial trafficking protein. Loss of MIRO2 blocks CAF reprogramming and tumor progression. • Clinically, MIRO2 is overexpressed at the invasive front of epithelial skin cancers, underscoring its relevance. • Beyond oncology, mitochondrial transfer may represent a broader mechanism of cell–cell communication relevant to tissue repair, development, and even non-cancer diseases. 💡 Why it matters: Targeting MIRO2 or mitochondrial transfer offers a new therapeutic strategy, especially for stroma-rich cancers like pancreatic cancer, where CAFs drive resistance and poor outcomes. 👉 Another step toward disrupting the tumor ecosystem and rethinking how cancer cells co-opt their microenvironment. #CancerResearch #TumorMicroenvironment #Fibroblasts #Mitochondria #PrecisionOncology #TranslationalScience Figure Courtesy: Michael Cangkrama. Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland

Nociceptive neurons promote gastric tumor progression Researchers have discovered that stomach cancers make electrical connections with nearby sensory nerves and use these malignant circuits to stimulate the cancer’s growth and spread. It is the first time that electrical contacts between nerves and a cancer outside the brain have been found, raising the possibility that many other cancers progress by making similar connections. Many different types of neurons are contained in the vagus nerve, but the researchers focused here on sensory neurons, which reacted most strongly to the presence of stomach cancer in mice. Some of these sensory neurons extended themselves deep into stomach tumors in response to a protein released by cancer cells called Nerve Growth Factor (NGF), drawing the cancer cells close to the neurons. After establishing this connection, tumors signaled the sensory nerves to release the peptide Calcitonin Gene Related Peptide (CGRP), inducing electrical signals in the tumor. The researchers could see this electrical activity with calcium imaging, a technique that uses fluorescent tracers that light up when calcium ions surge into a cell as an electrical impulse travels through. “There’s a circuit that starts from the tumor, goes up toward the brain, and then turns back down toward the tumor again,” the author says. It’s like a feed-forward loop that keeps stimulating the cancer and promoting its growth and spread.” For stomach cancer, CGRP inhibitors that are currently used to treat migraines could potentially short-circuit the electrical connection between tumors and sensory neurons. In the study, CGRP inhibitors administered to mice with stomach cancer reduced the size of the tumors, prolonged survival, and prevented the tumors from spreading. #ScienceMission #sciencenewshighlights https://lnkd.in/gcC6GENp

LUAD (Lung Adenocarcinoma) hijacks nociceptive sensory fibers to drive local immunosuppression; And cigarette smoke accelerates this independently of mutagenesis. Tumors locally amplify nociceptive sensory innervation, driving CGRP release. CGRP binds Ramp1 on a specific interstitial macrophage subset (TNFα+ CD74+), impairing their ability to engage CXCL13+ fibroblasts. The result: Failed TLS (Tertiary Lymphoid Structure) assembly. No TLS, no B/T cell coordination, no immune control. Sensory denervation reverses this: TLSs form, germinal centers mature, tumor growth decreases. The causal chain was confirmed stepwise: Denervation, CGRP blockade, macrophage depletion, CXCL13 neutralization, adoptive transfer of Ramp1-KO macrophages. Each link verified. Then the smoking revelation: Cigarette smoke extract selectively activates Nav1.8+ nociceptive neurons ex vivo & in vivo. Critically this occurred with no increase in TMB and no classical smoking-associated mutational signatures, a parallel tumor-promoting mechanism operating through neurogenic inflammation not DNA damage. This redefines how smoking promotes lung cancer. Chemogenetic silencing of sensory neurons or CGRP antagonism prior to anti-PD1 converted CSE-exposed non-responders into responders & extended survival. The therapeutic scaffold already exists: CGRP antagonists are approved for migraine. TCGA data confirms CALCA overexpression in ever-smokers and inverse correlation with TLS gene signatures. The axis, Nociceptive neuron → CGRP → Ramp1+ macrophage → CXCL13+ fibroblast → TLS, is mapped, potentially biomarker-trackable & druggable. #TumorInnervation #LUAD #NSCLC #Neuroimmunology #CancerNeuroscience #TLS #CGRP #CancerImmunotherapy #ImmunoOncology #Smoke #Cigarettes #Tobacco #LungCancer https://lnkd.in/dq-zJXBF

Recruitment of Immunosuppressive Cells and Immune Escape Recruitment of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and tumor-associated macrophages (TAMs), is an important mechanism by which tumors evade immune surveillance and suppress antitumor immunity. Cancer cells actively recruit these cells into the tumor microenvironment (TME) by secreting chemokines, cytokines, and growth factors. MDSCs are a heterogeneous population of cells that suppress T cell activation and promote tumor growth by producing arginase-1, nitric oxide, and reactive oxygen species (ROS). These factors inhibit T cell receptor (TCR) signaling, reduce effector T cell proliferation, and create a highly immunosuppressive microenvironment. Tregs play a crucial role in maintaining immune tolerance but are exploited by tumors to suppress antitumor immune responses. Tumors secrete CCL22 and other chemokines to attract Tregs, which suppress cytotoxic T lymphocyte (CTL) activity by producing suppressive cytokines, such as IL-10 and TGF-β. TAMs are often polarized to an M2-like phenotype within the TME, leading to immune evasion. M2-TAMs secrete VEGF, IL-10, and other factors that inhibit T cell function, promote angiogenesis, and support tumor progression. Their recruitment is mediated by tumor-secreted factors such as CSF-1 and CCL2. The cumulative effect of these immunosuppressive cells is to suppress antitumor immune responses, allowing tumors to grow uncontrollably. Targeting the recruitment and function of these cells is a promising strategy in cancer immunotherapy. Approaches include inhibiting chemokine pathways (e.g., CCR5, CCL2), reprogramming TAMs to an M1-like phenotype, or depleting Tregs and MDSCs to restore immune activity. By neutralizing the immunosuppressive influence of these cells, the TME can be reprogrammed to enhance the efficacy of immune checkpoint inhibitors and adoptive cell therapy. References [1] Yang Liu and Xuetao Cao, Journal of Molecular Medicine 2016 (DOI:10.1007/s00109-015-1376-x) [2] Yan Tie et al., Journal of Hematology & Oncology 2022 (doi: 10.1186/s13045-022-01282-8) #Immunotherapy #ImmuneEscape #CancerResearch #MDSCs #Tregs #TAMs #TumorMicroenvironment #CancerImmunology #OncologyUpdates #TargetedTherapy

Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth Significance: This study provides new insights into the mechanisms underlying the programming of CAFs and shows that during this process, expression of the cytokine IL33 is induced. CAF-derived IL33 has pleiotropic effects on the tumor microenvironment, supporting its potential as a therapeutic target. Pancreatic cancer is characterized by an extensive fibroinflammatory microenvironment. During carcinogenesis, normal stromal cells are converted to cytokine-high cancer-associated fibroblasts (CAF). The mechanisms underlying this conversion, including the regulation and function of fibroblast-derived cytokines, are poorly understood. Thus, efforts to therapeutically target CAFs have so far failed. Herein, we show that signals from epithelial cells expressing oncogenic KRAS—a hallmark pancreatic cancer mutation—activate fibroblast autocrine signaling, which drives the expression of the cytokine IL33. Stromal IL33 expression remains high and dependent on epithelial KRAS throughout carcinogenesis; in turn, environmental stress induces interleukin-33 (IL33) secretion. Using compartment-specific IL33 knockout mice, we observed that lack of stromal IL33 leads to profound reprogramming of multiple components of the pancreatic tumor microenvironment, including CAFs, myeloid cells, and lymphocytes. Notably, loss of stromal IL33 leads to an increase in CD8+ T-cell infiltration and activation and, ultimately, reduced tumor growth. Together, our findings shed light on the mechanisms through which cancer cells reprogram the stroma, particularly CAFs—mechanisms that could be targeted therapeutically to “normalize” fibroblasts in the setting of pancreatic cancer, as proposed (94). Our data demonstrate the rapid nature by which CAF polarization can shift due to the addition or loss of extracellular stimuli, further complicating potential efforts to establish sustained CAF reprograming as a therapeutic approach. Importantly, our use of the pharmacologic KRASG12D inhibitor, MRTX1133, showed a reduction of CAF IL33 expression that mirrored the genetic ablation of oncogenic KRAS, highlighting a potential synergistic effect whereby the TME may be reprogrammed in response to targeting cancer cells—a highly relevant observation, as KRASG12D inhibitors are currently entering the clinic (95, 96). Ultimately, targeting IL33 might provide a new avenue for combination therapy in pancreatic cancer. https://lnkd.in/enuqbkQ4

🔥 Few things excite me more than seeing #nerves and #cancer in the same sentence, and this study is a beautiful example of how far the field of cancer neuroscience has come. As someone who came into oncology from a neuroscience background, I’ve always analyzed cancer through a neural lens 🔍, so this newly published paper in JCI Insight (The Journal of Clinical Investigation family of journals) immediately stood out. Work by first author Ariana Sattler, PhD and colleagues at Oregon Health & Science University investigates pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and complex cancers, where the tumor microenvironment plays a central role in disease progression. The key discovery: 🔬 Sympathetic nerves (part of the stress-response system) and cancer-associated fibroblasts (CAFs) form a bidirectional feedback loop that promotes tumor progression. Here is what the study shows in mechanistic terms: 🔬 Sympathetic nerves infiltrating pancreatic tumors drive activation of CAFs 🔬 Activated CAFs remodel the extracellular matrix and tumor architecture in ways that support cancer progression 🔬 In turn, CAFs induce “nerve injury–like” transcriptional programs in sympathetic neurons, indicating active feedback from tumor stroma back to nerves 🔬Together, this creates a self-reinforcing neural–stromal loop within the tumor microenvironment 🔬 Importantly, experimental denervation reduced tumor growth in female mouse models, suggesting that neural input is functionally relevant 🔬 The sex-specific effect opens important and still unresolved questions about hormonal modulation of nerve–tumor interactions 🔬 The cover image depicts sympathetic ganglia (cyan) interacting with activated fibroblasts (white and cyan) in vitro, with cellular nuclei shown in dark blue. From a broader perspective, this work reinforces a major shift in oncology: tumor progression is shaped not only by cancer cell–intrinsic genetics and immune interactions, but also by dynamic bidirectional signaling between malignant cells, stromal populations, and the nervous system. We are only beginning to understand the full extent of neural regulation in cancer. That is precisely why cancer neuroscience has emerged as one of the most exciting and transformative frontiers in modern biomedical research. 🖇️ Link to the article in the comments: https://lnkd.in/gdEv4-Sh #CancerNeuroscience #PancreaticCancer #Oncology #ScienceCommunication #TumorMicroenvironment #BiomedicalResearch #PDAC

🧠✨ When Cancer Hijacks the Brain’s Wiring A remarkable new study in Nature (Savchuk et al., 2025) reveals that small cell lung cancer (SCLC) doesn’t just spread to the brain it integrates into its neural circuits. Researchers discovered that SCLC cells form functional synapses with neurons, tapping directly into the brain’s electrical signals to fuel their own growth. ⚡ These neuron-cancer connections act as “power lines,” giving tumors growth-promoting energy and making them even more aggressive. Even more intriguing in mouse models, blocking neural signaling sharply reduced tumor growth, and anti-seizure drugs that inhibit synaptic activity significantly shrank brain metastases. This work reshapes how we understand the nervous system’s role in cancer: the brain isn’t just a passive host it’s an active participant in tumor progression. 📄 Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis 👩🔬 Savchuk S. et al. 📚 Nature, 2025 | DOI: 10.1038/s41586-025-09492-z 💡 A stunning example of how cancer biology and neuroscience are converging opening new therapeutic possibilities where neurobiology meets oncology. #CancerResearch #Neuroscience #LungCancer #BrainMetastasis #NaturePaper #OncologyInnovation